Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Marked Increase in Psoriasis Seen With TNFi Use in Pediatric Inflammatory Diseases

Key clinical point: Psoriasis should be part of the risk-benefit conversation with families of pediatric patients with inflammatory diseases.

Major finding: Tumor necrosis factor inhibitor exposure was associated with a marked increase in psoriasis risk (hazard ratio, 3.84; 95% confidence interval, 2.28-6.47; P less than .001)

Study details: A review of 4,111 children

Disclosures: The National Institutes of Health funded the work. The investigators didn’t report any relevant disclosures.

Citation:

Buckley L et al. Arthritis Rheumatol. 2019;71(suppl 10), Abstract 1816.